.png){kind=icon}
.png){kind=icon}
Return
Bladder Cancer, Version 3.2024 Featured Updates to the NCCN Guidelines
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2024.0024.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non - muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guerin (BCG) -unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.
Keywords:
BACILLUS-CALMETTE-GUERIN
MITOMYCIN-C
SINGLE-ARM
OPEN-LABEL
METAANALYSIS
PEMBROLIZUMAB
RECURRENCE
RISK
MULTICENTER
CARCINOMA
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations